Abstract
Patient complaints arising as manifestations of medication side effects are commonly encountered in clinical practice. A rheumatologist must routinely consider side effects of drugs in the differential diagnosis of many symptoms. This review will remind the reader of certain well-described and some newly reported side effects commonly encountered in an internal medicine practice. Focal points incude arthralgias/arthritis, myopathy/myositis, ANA/drug-induced lupus, bone loss/osteoporosis, and tendon rupture.
Similar content being viewed by others
References and Recommended Reading
Nesher G, Zuckner J.: Rheumatologic complications of vitamin A and retinoids. Semin Arthritis Rheum 1995, 24:291–296.
Bewley AD, et al.: Isotretinoin causing aseptic arthropathy. Clin Exp Dermatol 1995, 20:279.
Carey BM, Parkin GJ, Cunliffe WJ, et al.: Skeletal toxicity with isotretinoin therapy: a clinico-radiographic evaluation. Br J Dermatol 1988, 119:609–614.
Anonymous: Adverse events following hepatitis B immunization. Aust Adv Drug React Bull 1996, 15:6.
Weibel RF, Benor DE: Chronic arthropathy and musculoskeletal symptoms associated with rubella vaccines: a review of 124 claims submitted to the National Vaccine Injury Compensation Program. Arthritis Rheum 1996, 39:1529–1534.
Berning SE, et al.: Adverse events associated with high dose Rifabutin in macrolide-containing regimens for the treatment of MAI complex lung disease. Clin Infectious Disease 1996, 22:885.
Knights SE, Leandro MJ, Khamashta MA, Hughes GR: Minocycline-induced arthritis. Clinical Exp Rheum 1998, 16:587–590.
Loeuille D, Gillet P, Netter P: Fluoroquinolone-induced arthralgia and MRI. J Rheumatol 1996, 23:1313–1314.
Bajaj S, Bell MJ, Shumak S, Briones-Urbina R: Antithyroid arthritis syndrome. J Rheumatol 1998, 25:1235–1239.
Tosun M, Guler M, Erem C, et al.: Intermittant polyarthritis due to PTU. Clin Rheumatol 1995, 14(5):574–575.
Meier CR, Jick H: Omeprazole, H2 blockers, and polyarthralgias: case-control study. BMJ 1997, 315:1283.
Plotz PH, et al.: Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis, and related disorders. Ann Intern Med 1989, 111(2):143–157.
England, HDF, et al.: Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors: simvastatin and pravastatin. Aust NZ J Med 1995, 25:374–375.
Jonas GB: Increased incidence of myositis in patients treated with high dose simvastatin. Am J of Cardiol 1998, 81(2):259.
Horn, M: Coadministration of itraconazole with hypolipidemic agents may induce rhabdomylysis in healthy individuals. Arch Dermatol 1996, 132:1254.
Neuronen PJ, et al.: Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Therapy 1996, 60:54–61.
Jacobson RH, Wang P, Glueck CJ: Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone. JAMA 1997, 227(4):296.
Chariot, et al.: Cytochrome C oxidase deficiency in zidovudine myopathy affects perifascular muscle fibers and arterial smooth muscle cells. Neuropathol Appl Neurobiol 1995, 21:540–547.
Sinnwell, TM, et al.: Metabolic abnormalities in skeletal muscle of patients receiving zidovudine therapy observed by 31P in vivo magnetic resonance spectroscopy. J Clin Invest 1995, 96:126–131.
Dienstag JL, et al.: A preliminary trial of lamivudine for chronic hepatitis B infection. N Eng J Med 1995, 333:1657–1661.
Finger DR, Plotz PH, Heywood G: Myositis following treatment with high dose IL-2 for malignancy. J Rheum 1994, 21(4):752–753.
Alloway JA, Salata MP: Quinidine-induced rheumatic syndromes. Semin Arthritis Rheum 1995, April, (5):315–322.
Hess E: Drug-related Lupus. N Engl J Med 1988, 11(22):1460–1462.
Yung R, Chang S, Hemati N, et al.: Mechanisms of druginduced lupus: IV. Comparison of procainamide and hydralazine with analogs in vitro and in vivo. Arthritis Rheum 1997, 40(8):1436–1443.
Masson C, Chevailler A, Pascaretti C, et al.: Minocycline related lupus. J Rheum 1996, 23:2160–2161.
Uzzan B, Campos J, Cucherat M, et al.: Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 1996, 81(12):4278–4289.
Schneider DL, et al.: Thyroid hormone use and bone mineral density in elderly women: effect of estrogen. JAMA 1994, 271:1245–1249.
Struijs A, Mulder H: The effects of inhaled glucocorticoids on bone mass and biochemical markers of bone homeostasis: a 1-year study of beclomethasone vs. budesonide. Netherlands J Med 1997, 50:233–237.
Anonymous: ommendations for the prevention and treatment of glucocorticoid-induced osteoporosis Arthritis Rheum 1996 39(11):1791–1801.
Adachi JD, et al.: Vitamin D and calcium in the prevention of corticosteroid-induced osteoporosis: a 3-year follow-up. J Rheumatol 1996, 23:995–1000.
Eastell R, on behalf of UK Consensus Group Meeting on Osteoporosis Management of Corticosteroid Induced Osteoporosis: J Intern Med 1995, 237:419–447.
Saag HG, Emkey R, Schnitzer TJ, et al.: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis: Glucocorticoid-induced Osteoporosis Intervention Study Group. N Engl J Med 1998, 339:292–299.
Sivakumaran M, Ghosh K, Zaidi Y, Hutchinson RM:Osteoporosis and vertebral collapse following low-dose LMWH therapy in a young patient. Clin Lab Hematol 1996, 18:55–57.
Nightingale, SL: From the Food and Drug Administration. JAMA 1996, 276:774.
Pai VS: Rupture of the plantar fascia. J Foot Ankle Surg 1996, 35:9–40.
Aronson JK: Side Effects of Drugs Annual 20 1997. UK:Elsevier Publishers; 1997.
Aronson JK. Side Effects of Drugs Annual 21 1998. UK:Elsevier Publishers; 1998.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brenner, J., Solitar, B.M. & Golden, B.D. Rheumatic manifestations of current pharmacopeia. Curr Rheumatol Rep 2, 151–155 (2000). https://doi.org/10.1007/s11926-000-0055-1
Issue Date:
DOI: https://doi.org/10.1007/s11926-000-0055-1